PubMed Health⌕ Search

Biomedical subjects

Neil Scolding

Publications and source records attributed to Neil Scolding.

7 recordsLinked to original sources
PubMed2004

Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases.

The standard therapy for episodes of severe acute inflammatory demyelinating disease of the central nervous system is high dose intravenous corticosteroids. A small proportion of patients fail to improve with this regime and their prognosis can become grave. A recent sham controlled double blind crossover trial in this group of patients demonstrated a significant benefit from plasma exchange. We report six patients with severe acute steroid-insensitive inflammatory demyelinating disease of the central nervous system treated with plasma exchange. We observed a clear improvement in five of these six patients. Whilst complications of plasma exchange occurred these did not outweigh the benefits. Our study supports the use of plasma exchange in severe acute steroid-insensitive inflammatory disease of the central nervous system.

Adolescent↗
PubMed2004

Cell therapy in demyelinating diseases.

Multiple sclerosis presents particular and serious problems to those attempting to develop cell-based therapies: the occurrence of innumerable lesions scattered throughout the CNS, axon loss, astrocytosis, and a continuing inflammatory process, to name but a few. Nevertheless, the limited and relatively focused nature of damage to oligodendrocytes and myelin, at least in early disease, the large body of available knowledge concerning the biology of oligodendrocytes, and the success of experimental myelin repair, have allowed cautious optimism that therapies may be possible. Here, we review the clinical and biological problems presented by multiple sclerosis in the context of cell therapies, and the neuroscientific background to the development of strategies for myelin repair. We attempt to highlight those areas where difficulties have yet to be resolved and draw on a variety of more recent experimental findings to speculate on how remyelinating therapies are likely to develop in the foreseeable future.

Animals↗
PubMed2002

Cell transplantation, myelin repair, and multiple sclerosis.

A decade ago, therapeutic strategies to remyelinate the CNS in diseases such as multiple sclerosis had much experimental appeal, but translation of laboratory success into clinical treatments appeared to be a long way off. Within the past 12 months, however, the first patients with multiple sclerosis have received intracerebral implants of autologous myelinating cells. Here we review the clinical and biological problems presented by multiple sclerosis disease processes, and the background to the development of myelin-repair strategies. We attempt to highlight those areas where difficulties have yet to be resolved, and draw on various experimental findings to speculate on how remyelinating therapies are likely to develop in the foreseeable future.

Animals↗
PubMedDate not supplied

Subacute neurological syndromes.

Sudden onset neurological syndromes are almost always vascular but there is a wide range of causes of subacute onset neurological syndromes. Most diagnoses will become clear from clinical assessment and, depending on presentation, computed tomography or magnetic resonance imaging of the brain or spine and cerebrospinal fluid examination. When investigations have proved negative, paraneoplastic neurological diseases and Creutzfeldt-Jakob disease should be considered.

Acute Disease↗